AKRX - Akorn, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.3400
-0.1100 (-2.47%)
At close: 4:00PM EDT

4.3400 0.00 (0.00%)
After hours: 5:20PM EDT

Stock chart is not supported by your current browser
Previous Close4.4500
Open4.4400
Bid4.3000 x 3200
Ask4.4000 x 4000
Day's Range4.2800 - 4.4400
52 Week Range2.6400 - 19.6500
Volume827,127
Avg. Volume2,320,612
Market Cap546.189M
Beta (3Y Monthly)2.19
PE Ratio (TTM)N/A
EPS (TTM)-3.6290
Earnings DateAug 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date1991-05-24
1y Target Est6.60
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Akorn to Report Second Quarter 2019 Financial Results and Host Conference Call

    Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release before market open on Thursday, August 1, 2019 outlining its second quarter 2019 financial results. In addition, the Company has scheduled a conference call at 9:00 a.m. ET on the same day to discuss its second quarter 2019 financial results. To access the webcast replay, please go to Akorn’s Investor Relations web site at http://investors.akorn.com.

  • Markit6 days ago

    See what the IHS Markit Score report has to say about Akorn Inc.

    Akorn Inc NASDAQ/NGS:AKRXView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for AKRX with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on July 5. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding AKRX totaled $62.55 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire17 days ago

    Akorn Announces Launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5%

    Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that it has launched its first-to-market generic of Loteprednol Etabonate Ophthalmic Suspension, 0.5%. According to IQVIA, U.S. sales of Loteprednol Etabonate Ophthalmic Suspension, 0.5% were approximately $90 million for the twelve months ended April 2019.

  • Did Hedge Funds Drop The Ball On Akorn, Inc. (AKRX) ?
    Insider Monkey18 days ago

    Did Hedge Funds Drop The Ball On Akorn, Inc. (AKRX) ?

    Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved dearly, lost nearly 40% of its value at one point in 2018. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 20 S&P 500 […]

  • Benzinga20 days ago

    Akorn Receives FDA Warning Letter, Says It's Committed To Resolving Issues

    Generic pharmaceuticals manufacturer Akorn, Inc. (NASDAQ: AKRX) said Tuesday that it received a warning letter from the Food and Drug Administration related to the inspection of its Somerset, New Jersey manufacturing facility in July and August 2018. Akorn said it is committed to the highest standards of quality and compliance and will continue to work collaboratively with the FDA to resolve issues addressed in the warning letter.

  • Reuters20 days ago

    Akorn gets FDA warning letter for another manufacturing plant

    The FDA warning is the second that Akorn has received this year and follows an inspection of the company's Somerset, New Jersey-based plant in July and August 2018. In January, the agency issued a warning letter for Akorn's other manufacturing plant in Decatur, Illinois after the drugmaker did not resolve previously highlighted violations such as failure to follow procedures to prevent contamination of drugs produced at the plant.

  • Akorn Files Complaint on Fresenius' Canceled Bid
    Investopedia20 days ago

    Akorn Files Complaint on Fresenius' Canceled Bid

    Akorn said it will 'vigorously' protest Fresenius' plans to drop its planned $4.75B acquisition.

  • TheStreet.com20 days ago

    Drugmaker Akorn Receives FDA Warning Letter Regarding N.J. Facility

    said Tuesday that it received a warning letter from the U.S. Food & Drug Administration regarding an inspection of the company's Somerset, New Jersey facility in July and August 2018. The Lake Forest, Illinois-based company said in a statement that it will respond to the FDA letter within the required 15 working days. "Akorn is committed to resolving the warning letter in a comprehensive and effective manner," Douglas Boothe, president and CEO, said in the statement.

  • Reuters20 days ago

    UPDATE 3-Akorn gets FDA warning letter for another manufacturing plant

    Akorn Inc said on Tuesday it received a warning letter from the U.S. Food and Drug Administration regarding its manufacturing facility in New Jersey, the latest in a string of setbacks for the generic drugmaker. The FDA warning is the second that Akorn has received this year and follows an inspection of the company's Somerset, New Jersey-based plant in July and August 2018. In January, the agency issued a warning letter for Akorn's other manufacturing plant in Decatur, Illinois after the drugmaker did not resolve previously highlighted violations such as failure to follow procedures to prevent contamination of drugs produced at the plant.

  • MarketWatch20 days ago

    Generics maker Akorn receives warning letter from the FDA relating to NJ facility

    Generics company Akorn Inc. said Tuesday it has received a warnings letter from the U.S. Food and Drug Administration, relating to the inspection of a facility in New Jersey in July and August of 2018. The company said it is committed to the highest levels of quality and compliance and will work with the regulator to address all issues raised in the letter. "Earlier this year, Akorn launched a company-wide action plan to improve the timing and effectiveness of our operations, quality systems and compliance enhancement initiatives, with an emphasis on transparency and quality," Akorn Chief Executive Douglas Boothe said in a statement. The company remains confident in the quality of products made at the facility, which is located in Somerset. Shares were halted for the news, but have gained 39.5% in 2019, while the S&P 500 has gained 17.5%.

  • GlobeNewswire20 days ago

    Akorn Receives FDA Warning Letter

    Akorn is committed to the highest standards of quality and compliance, and will continue to work collaboratively with the FDA to resolve all issues addressed in the warning letter.  The Company will respond to the FDA letter within the required 15 working days from receipt of the letter. Douglas Boothe, Akorn’s President and Chief Executive Officer, stated, “Akorn is committed to resolving the warning letter in a comprehensive and effective manner.

  • How Many Akorn, Inc. (NASDAQ:AKRX) Shares Did Insiders Buy, In The Last Year?
    Simply Wall St.last month

    How Many Akorn, Inc. (NASDAQ:AKRX) Shares Did Insiders Buy, In The Last Year?

    We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

  • GlobeNewswire2 months ago

    Akorn to Present at the Jefferies 2019 Global Healthcare Conference

    Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that management will present at the Jefferies 2019 Global Healthcare Conference on Friday, June 7, 2019 at 9:30 a.m. EDT in New York, NY. A live webcast of the presentation can be accessed in the investor relations portion of Akorn's website at http://investors.akorn.com/events-and-presentations. The webcast may include forward-looking statements about, among other things, the Company’s business plans and initiatives, the Company’s commitments to the FDA and remediation efforts, disruptions during the Standstill Period, the Company’s anticipated future operating and financial performance, business plans and prospects, product pipeline, including filings, approvals and launches, capital allocation, debt refinancing, and potential dispositions, that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 20) Kaleido Biosciences Inc (NASDAQ: KLDO ) Down In The ...

  • GlobeNewswire2 months ago

    Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1%

    LAKE FOREST, Ill., May 20, 2019 -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug.

  • GlobeNewswire2 months ago

    Akorn to Present at the RBC Capital Markets Healthcare Conference

    Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that management will present at the 2019 RBC Capital Markets Healthcare Conference on Wednesday, May 22, 2019 at 2:05 p.m. EDT in New York, NY. A live webcast of the presentation can be accessed on the investor page of Akorn's website at http://investors.akorn.com. A replay of the webcast will also be available for 90 days on Akorn's website following the conference.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of AKRX earnings conference call or presentation 7-May-19 2:00pm GMT

    Q1 2019 Akorn Inc Earnings Call

  • Here’s What Hedge Funds Think About Akorn, Inc. (AKRX)
    Insider Monkey2 months ago

    Here’s What Hedge Funds Think About Akorn, Inc. (AKRX)

    While the market driven by short-term sentiment influenced by uncertainty regarding the future of the interest rate environment in the US, declining oil prices and the trade war with China, many smart money investors kept their optimism regarding the current bull run in the fourth quarter, while still hedging many of their long positions. However, […]

  • Akorn (AKRX) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Akorn (AKRX) Q1 2019 Earnings Call Transcript

    AKRX earnings call for the period ending March 31, 2019.

  • Akorn (AKRX) Reports Q1 Loss, Tops Revenue Estimates
    Zacks2 months ago

    Akorn (AKRX) Reports Q1 Loss, Tops Revenue Estimates

    Akorn (AKRX) delivered earnings and revenue surprises of 28.57% and 8.44%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Akorn: 1Q Earnings Snapshot

    On a per-share basis, the Lake Forest, Illinois-based company said it had a loss of 65 cents. Losses, adjusted for one-time gains and costs, came to 10 cents per share. The results exceeded Wall Street ...

  • GlobeNewswire2 months ago

    Akorn Provides Preliminary First Quarter 2019 Results and Full Year Guidance

    -Operational improvements drive sequential growth- -Full year outlook anticipates further sequential growth throughout the year- LAKE FOREST, Ill., May 07, 2019 -- Akorn,.